Niagen Bioscience Q3 sales fall, miss estimates
NAGE•Niagen Bioscience reported Q3 net sales of $27.19 million, below the $32.06 million analyst consensus, and a net loss of $1.17 million. The company expects 2026 direct website revenue to grow 15% to 20%, while ingredient business revenue is expected to decline.
1. Quarterly results
Q3 net sales fell to $27.19 million, missing analyst expectations of $32.06 million, and the company posted a net loss of $1.17 million. Adjusted EBITDA was positive for the quarter.
2. 2026 outlook
Niagen Bioscience expects direct website revenue to grow 15% to 20% year over year in 2026 and overall e-commerce revenue to increase about 5%. It expects its ingredient business to decline due to lower volume from key partners.
3. Sales channels and products
Direct-to-consumer website sales grew 13% year over year. During the quarter, the company introduced the Niagen Plus At-Home Injection Kit and Niagen NanoCloud topical product; Tru Niagen launched on Walmart.com and in nearly 300 GNC and Sam’s Club locations across 44 states.
